BIVV020 - A Safety and Tolerability Study of BIVV020 in Adults with Cold Agglutinin Disease Phase 1 Sanofi Genzyme
https://clinicaltrials.gov/ct2/show/NCT04269551
Recruiting
Estimated Completion Date November 2021
BIVV009 - (Sutimlimab - press release May 14, 2020 ) A Study to Assess the Efficacy and safety of BIVV009 in Participants With Primary Cold Agglutinin Diseases Without A Recent History of Blood transfusion (Cadenza Study) Phase 3 Sanofi Genzyme
https://clinicaltrials.gov/ct2/show/NCT03347422
Active, Not Recruiting
Estimated Completion Date December 2021
Efficacy, Safety and Pharmacokinetics of Rilizabrutinib in Patients with Warm Autoimmue Hemolytic Anemia (wAIHA) This is a single group treatment, Phase 2 open-label, study to evaluate the efficacy, safety and pharmacokinetics of rilizabrutinib in adult patients with wAIHA.
As of September 29, 2021 Active, Not Recruiting YET
Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmunce Hemolytic Anemia (wAIHA). Part A: To evaluate the safety and tolerability of subcutaneous injections of isatuximab in adults with wAIHA Part B: To evaluate the efficacy of the selected dose in adults with wAIHA
Active, Recruiting
We are writing to introduce ourselves and to share some exciting cold agglutinin disease (CAD) news. Apellis is a development stage, global biopharmaceutical company that was established 10 years ago to combine courageous science, creativity, and compassion to deliver life-changing medicines for a broad range of serious diseases.
A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD) Swedish Orphan Biovitrum. Click Here
Active, Recruiting Last Updated Post March 7, 2022 Estimated Completion Date June 2024
A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with Cold Agglutinin Disease (CAD)
Brief Summary:
Phase 3 - The purpose of the study is to determine the efficacy of pegcetacoplan administration compared to placebo in increasing hemoglobin (Hgb) level from baseline and avoiding transfusion in participants with primary cold agglutinin disease (CAD).
